Skip to main content

Table 2 Univariate analysis of the infections in the MM patients

From: Assessment of infection in newly diagnosed multiple myeloma patients: risk factors and main characteristics

Factors

Investigated cases

(n = 161)

Group with infections (%)

(n = 126)

Group without infections (%)

(n = 35)

χ2

P value

Sex

   

3.132

0.077

 Male

94

69 (73.4)

25 (26.6)

  

 Female

67

57 (85.1)

10 (14.9)

  

Age

   

2.583

0.108

 <60

51

36 (70.6)

15 (29.4)

  

  ≥ 60

110

90 (81.8)

20 (18.2)

  

ECOG score

   

4.294

0.038

  ≤ 2

100

73 (73.0)

27 (27.0)

  

 >2

61

53 (86.9)

8 (13.1)

  

Immunophenotype

   

0.672

0.880

 IgG

70

54 (77.1)

16 (22.9)

  

 IgA

49

39 (79.6)

10 (20.4)

  

 Light chain

32

26 (81.3)

6 (18.8)

  

 Others

10

7 (70.0)

3 (30.0)

  

Durie-Salmon stage

   

6.540

0.011

 Stage I-II

36

23 (63.9)

13 (36.1)

  

 Stage III

122

102 (83.6)

20 (16.4)

  

ISS stage

   

7.728

0.005

 Stage I-II

56

37 (66.1)

19 (33.9)

  

 Stage III

101

86 (85.1)

15 (14.9)

  

RBC (/L)

   

0.448

0.503

  < 3.8 × 1012(f);

153

121 (79.1)

32 (20.9)

  

  < 4.3 × 1012(m)

≥3.8 × 1012(f); ≥4.3 × 1012(m)

8

5 (62.5)

3 (37.5)

  

Haemoglobin (g/L)

   

6.092

0.014

 <90

98

83 (84.7)

15 (15.3)

  

  ≥ 90

63

43 (68.3)

20 (31.7)

  

ANC (/L)

   

0.000

1.000

 <1.5 × 109

19

15 (78.9)

4 (21.1)

  

  ≥ 1.5 × 109

142

111 (78.2)

31 (21.8)

  

ALC (/L)

   

3.676

0.055

  < 1.0 × 109

38

34 (89.5)

4 (10.5)

  

  ≥ 1.0 × 109

123

92 (74.8)

31 (25.2)

  

CRP (mg/L)

   

7.235

0.007

  ≤ 10

95

69 (72.6)

26 (27.4)

  

 >10

62

56 (90.3)

6 (9.7)

  

Albumin (g/L)

   

3.155

0.076

 <35

111

91 (82.0)

20 (18.0)

  

  ≥ 35

49

34 (69.3)

15 (30.6)

  

Globulin (g/L)

   

0.056

0.813

  ≤ 30

39

31 (79.5)

8 (20.5)

  

 >30

121

94 (77.7)

27 (22.3)

  

Serum creatinine (μmol/L)

   

0.450

0.502

 <177

117

90 (76.9)

27 (23.1)

  

  ≥ 177

44

36 (81.8)

8 (18.2)

  

Serum calcium (mmol/L)

   

0.651

0.420

  ≤ 2.75

149

115 (77.2)

34 (22.8)

  

 >2.75

12

11 (91.7)

1 (8.3)

  

β2-MG (mg/L)

   

1.805

0.179

 <5.5

69

51 (73.9)

18 (26.1)

  

  ≥ 5.5

87

72 (82.8)

15 (17.2)

  

LDH (U/L)

   

0.124

0.725

  ≤ 243

105

85 (81.0)

20 (19.0)

  

 >243

32

25 (78.1)

7 (21.9)

  

Bone destruction

   

3.581

0.058

 Yes

99

82 (82.8)

17 (17.2)

  

 No

60

42 (70.0)

18 (30.0)

  

Invasive operation

   

1.193

0.275

 Yes

138

110 (79.7)

28 (20.3)

  

 No

23

16 (69.6)

7 (30.4)

  

Renal dysfunction

   

1.213

0.271

 Yes

52

38 (30.2)

14 (40.0)

  

 No

109

88 (69.8)

21 (60.0)

  

Cardiac dysfunction

   

0.373

0.541

 Yes

31

23 (18.3)

8 (22.9)

  

 No

130

103 (81.7)

27 (77.1)

  

Hypertension

   

0.814

0.367

 Yes

63

47 (37.3)

16 (45.7)

  

 No

98

79 (62.7)

19 (54.3)

  

Diabetes

   

0.915

0.229

 Yes

24

17 (13.5)

7 (20.0)

  

 No

137

109 (86.5)

28 (80.0)

  
  1. ECOG Eastern Cooperative Oncology Group, ISS International Staging System, RBC Red Blood Cells, f female, m male, ANC Absolute Neutrophil Count, ALC Absolute Lymphocyte Count, CRP C-reactive protein, β2-MG β2-microglobulin, LDH lactate dehydrogenase
  2. Reference ranges of the laboratory values in our study: RBC 3.8 ~ 5.1 × 1012 (f), 4.3 ~ 5.8 × 1012/L(m); CRP ≤ 10 mg/L.
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us